The effect of Ginger powder consumption on inflammation and Immunity in Rheumatoid arthritis disease

INTERVENTION: Control groups: Patients that refer to hospital shariatti have interval criteria and will receive starch or flour voluntarily. Patients in Control group will receive 1500 mg of wheat flour daily (by two 750 mg capsules) one 750 mg capsule before lunch and one before dinner for 3 months. Intervention 1: Intervention Group: Patients that refer to hospital shariatti have interval criteria and will receive Ginger voluntarily. Patients in case group will receive 1500 mg of powdered Ginger daily (by two 750 mg capsules) for 3 months ne 750 mg capsule before lunch and one before dinner for 3 months. Intervention 2: Control groups: Patients that refer to hospital shariatti have interval criteria and will receive starch or flour voluntarily. Patients in Control group will receive 1500 mg of wheat flour daily (by two 750 mg capsules) one 750 mg capsule before lunch and one before dinner for 3 months. Intervention Group: Patients that refer to hospital shariatti have interval criteria and will receive Ginger voluntarily. Patients in case group will receive 1500 mg of powdered Ginger daily (by two 750 mg capsules) for 3 months ne 750 mg capsule before lunch and one before dinner for 3 months. Placebo Treatment ‐ Other CONDITION: adult active Rheumatoid arthritis. ; Rheumatoid arthritis, unspecified Rheumatoid arthritis, unspecified PRIMARY OUTCOME: DAS28. Timepoint: Before and after study. Method of measurement: using ESR,CRP and number of joints with inflammation. ESR. Timepoint: Before and after the study. Method of measurement: Westergern method. HsCRP. Timepoint: Before and after intervention. Method of measurement: Elisa. IL10. Timepoint: Before and after treatment. Method of measurement: ELISA. IL17. Timepoint: Before and after intervention. Method of measurement: ELISA. IL2. Timepoint: Before and after intervention. Method of measurement: ELISA. IL4. Timepoint: Before and after treatment. Method of measurement: ELISA. TNFa. Timepoint: Before and after intervention. Method of measurement: ELISA. SECONDARY OUTCOME: BMI. Timepoint: Before and after intervention. Method of measurement: weight(kg)/height(m*2). Nsaids intake. Timepoint: Before and after intervention. Method of measurement: questionnaire. INCLUSION CRITERIA: INCLUSION CRITERIA: person with RA diseases as ACR criteria, having RA from 2 years ago; age between 18‐69 years; not being pregnant or lactated; not smoking and drink alcohol; haven’t eaten multivitamin or antioxidants supplements from 3 month ago; don't eat lowering blood pressure; don't eat anti pregnancy drugs, exclusion criteria: Changes in diet or physical activity every day; taking less than 80% of supplements given to patients at baseline(the compliance lower than %80); consumption of contraceptives, multivitamins and antioxidant supplements; renal , hepatic , thyroid, parathyroid diseases, cancer, heart diseases